Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in BIO-...

2026-10-23 10:07 591

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the disc...

2026-10-23 08:02 1501

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011,will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These p...

2026-10-23 08:00 838

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consol...

2026-10-22 20:00 1200

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

* Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity * Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...

2026-10-22 18:00 1702

Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission

SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA...

2026-10-22 13:30 1382

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

* Becomes the 7th International Registrational Clinical Trial for Ivonescimab * Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its ...

2026-10-21 20:42 2067

China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"),today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termi...

2026-10-21 20:00 2334

Samsung Biologics Reports Third Quarter 2026 Financial Results

* Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion * Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance * Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion...

2026-10-21 15:00 2576

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

* 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care. * More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted anti...

2026-10-21 10:09 1454

AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™

Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach AUCKLAND, New Zealand, Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an exclusive ag...

2026-10-21 08:00 1917

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment

* Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. * Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone payment from Servier. * The multi-t...

2026-10-20 21:00 2970

New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD

A Collaboration Leads to Molecularbiological Innovation MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAM...

2026-10-20 14:10 1131

New Innovative Molecular Technology Combination

Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication

Advancing Commercialization Preparations to Expand Injectables Presence in China HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today a...

2026-10-20 09:00 2054

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year. Frost & S...

2026-10-20 08:00 2801

Versiti becomes 10th U.S. blood center to adopt FDA-cleared automation from Terumo Blood and Cell Technologies

Automated whole blood processing will expand platelet production capacity and help meet growing hospital demand LAKEWOOD, Colo. and MILWAUKEE, Oct. 19, 2026 /PRNewswire/ -- Versiti has become the 10th U.S. blood center to adopt the Reveos™ Automated Blood Processing System

2026-10-19 22:00 4251

Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026

Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion Ba...

2026-10-19 21:00 2563

Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer

SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this role, Ms. Ma will oversee the Company's financi...

2026-10-19 20:00 1722

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit TherapeuticsInc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built on Akeso's first-in-class immuno-oncology (IO) c...

2026-10-19 19:59 1957

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data onits Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally...

2026-10-19 10:00 3610

12 3 4 5 ... 166